The following article requires a subscription:

(Format: HTML, PDF)

: Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy.

Copyright (C) 2016 by the International Association for the Study of Lung Cancer